Treprostinil Sodium Improves Exercise Capacity When Added to Existing Oral Pulmonary Arterial Hypertension Therapy

Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations

“…Stability at room temperature, a half-life of ϳ4 hours 6 and a neutral pH allow treprostinil to be administered by either continuous SC or intravenous (IV) infusion. Treprostinil has demonstrated efficacy in the treatment of PAH when administered by either route 5,[7][8][9][10][11][12][13][14][15][16][17] ; however, infusion site pain, a common side effect associated with SC treprostinil, has limited the appeal of SC treprostinil to patients and physicians. Clinical experiences at PAH specialty centers have provided new insight regarding dosing and management of infusion site pain, which has led to improved clinical benefit from SC treprostinil.…”

Current and Emerging Therapies in Pulmonary Arterial Hypertension: Focus on Treprostinil

“…Treprostinil is frequently used in combination with oral therapies including PDE-5i and ETa's, although relatively few trials have studied combination therapy. 66,67 A retrospective study of 38 patients treated with subcutaneous treprostinil showed improved functional class, 6-minute walk distance, Borg dyspnea score, and hemodynamics. Nineteen patients had bosentan added and were found to have additional improvement in pulmonary arterial pressure, 6-minute walk distance, and Borg dyspnea scale compared to baseline.…”

“…66 Among 20 patients with PAH in a multicenter open-label 12 week study who were treated with oral therapy (a PDE-5i, ETa, or both) who had continuous IV or SC treprostinil sodium added to their treatment, there was a 35 meter improvement in 6-minute hall walk by week 12 with a trend toward improvement in Borg dyspnea score. 67 Of the 20 patients, three discontinued therapy prematurely; one had a central line infection, one died due to worsening PAH, and one was lost to follow-up. Combination therapy was well-tolerated.…”